 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Journal: Folliculotropic Mycosis Fungoides of the face successfully treated combining CO2 laser and conventional photodynamic therapy (c-PDT). (Pubmed Central) - Dec 13, 2024
The primary endpoint was the clinical remission of the lesions; the secondary one the evaluation of treatment tolerance, measured using the 11-point (0-10) Numeric Rating Scale (NRS) for burning/pain, heat, and swelling. After a single treatment session and four weeks of follow-up, the patient's facial lesions achieved complete clinical remission.
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Clinical data, Journal: Photodynamic therapy light': An enhanced treatment protocol for actinic keratoses with minimal pain and optimal clinical outcome by combining laser-assisted low irradiance PDT with shortened daylight PDT. (Pubmed Central) - Oct 19, 2024
The novel 'PDT light' protocol proved to be an excellent and nearly painless method with an average visual-analogue scale (VAS) score of 1.19. Additional advantages included reduced illumination time, shorter outpatient stays in the clinic, fewer adverse effects, and better patient compliance than with DLPDT alone.
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Successful Treatment of Hailey-Hailey Disease with Photodynamic Therapy: A Case Report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3680;
Additional advantages included reduced illumination time, shorter outpatient stays in the clinic, fewer adverse effects, and better patient compliance than with DLPDT alone. We performed PDT treatment in the axillary and left sub-mammary regions following methyl aminolevulinate (Metvixia
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Journal: Efficacy of photodynamic therapy using ALAHCl in gel with a lipid nanoemulsion and MALHCl in cream in superficial basal cell carcinoma. (Pubmed Central) - Apr 2, 2024
Both formulations - ALA-HCl in gel and MAL-HCl in cream - were highly effective photosensitisers for PDT. The advantage of ALA-HCl in a gel formulation with a lipid nanoemulsion was faster skin healing, resulting in better cosmetic results.
- ||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion, Enrollment change: ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis (clinicaltrials.gov) - Feb 23, 2024
P=N/A, N=224, Completed, Sponsor: Galderma Laboratorium GmbH
The advantage of ALA-HCl in a gel formulation with a lipid nanoemulsion was faster skin healing, resulting in better cosmetic results. Recruiting --> Completed | N=350 --> 224
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Clinical, Journal: Keratolytics can replace curettage in daylight photodynamic therapy for actinic keratosis on the face/scalp: A randomized clinical trial. (Pubmed Central) - Dec 10, 2023
According to our results, curettage is not necessary to obtain the full treatment effect of n-DL-PDT. We experienced in a real-life setting that n-DL-PDT protocol could be changed by replacing curettage with keratolytics.
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion date: New Treatments for Actinic Keratoses of the Scalp (clinicaltrials.gov) - Nov 21, 2023
P=N/A, N=120, Active, not recruiting, Sponsor: Helsinki University Central Hospital
We experienced in a real-life setting that n-DL-PDT protocol could be changed by replacing curettage with keratolytics. Trial completion date: Jul 2024 --> Dec 2024
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion, Trial primary completion date: Dermaris-35: Clinical Evaluation of a Short Illumination Duration (35 Minutes) When Performing PDT of AK Using the Dermaris (clinicaltrials.gov) - Oct 18, 2023
P=N/A, N=25, Completed, Sponsor: Centre Dermatologique du Roy
Trial completion date: Jul 2024 --> Dec 2024 Recruiting --> Completed | Trial primary completion date: Dec 2022 --> Jun 2023
- ||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial termination: A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov) - Oct 10, 2023
P3, N=125, Terminated, Sponsor: Galderma R&D
Recruiting --> Completed | Trial primary completion date: Dec 2022 --> Jun 2023 Completed --> Terminated; The study was terminated early as per Sponsor's decision
- Ameluz (aminolevulinic acid) / Biofrontera
Photodynamic therapy with BF-200 ALA and red-light for the treatment of non-aggressive BCCs: 5-year follow-up data of a randomized, controlled, comparative multicenter phase-III-trial (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3147;
P3
Materials & 272 adult subjects with 1-3 primary nodular or superficial BCCs ?2 mm thickness on face/scalp, neck/trunk or extremities were randomized (1:1) to receive up to 4 PDTs with 7.8% aminolevulinic acid (ALA) gel (BF-200 ALA) or 16% methyl-aminolevulinate (MAL) cream. The initial and sustainable high clearance rates and the high patient satisfaction demonstrate that PDT is an effective and sustainable treatment option for BCCs.
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion date, Trial primary completion date: ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis (clinicaltrials.gov) - Jul 31, 2023
P=N/A, N=350, Recruiting, Sponsor: Galderma Laboratorium GmbH
The initial and sustainable high clearance rates and the high patient satisfaction demonstrate that PDT is an effective and sustainable treatment option for BCCs. Trial completion date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Photodynamic Therapy of Acne Using Methyl Aminolevulinate Hydrochloride cream in Korean Adolescent Patients () - Jul 3, 2023 - Abstract #WCD2023WCD_4555;
Trial completion date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023 PDT may be an effective and safe treatment for adolescent acne patients who are difficult to treat with oral antibiotics or retinoid-based topical agents.
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
PDT Light: minimal pain, maximal effect. An enhanced method of a laser-assisted very-low-irradiance-PDT, combined with a shortened daylight illumination (Level 3 - Room 327) - Apr 24, 2023 - Abstract #WCD2023WCD_1837;
PDT may be an effective and safe treatment for adolescent acne patients who are difficult to treat with oral antibiotics or retinoid-based topical agents. 7.6 +/-1,5 by a different author) at face and scalp during illumination after using MAL-cream and the Aktilite-LED with a fluence rate of 74 mW/cm
- |||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New trial: ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis (clinicaltrials.gov) - Feb 13, 2023
P=N/A, N=350, Recruiting, Sponsor: Galderma Laboratorium GmbH
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma, Ameluz (aminolevulinic acid) / Biofrontera
Topical and Intralesional photodynamic therapy for hidradenitis suppurativa: A retrospective case series study of the University Hospital Son Espases. (Room 2) - Feb 2, 2023 - Abstract #EHSF2023EHSF_78;
A third option for lesions deeper than 8mm could be the use of intralesional ALA and intralesional diode laser of 630nm. PDT seems to be cost-effective, safe, and well-tolerated local therapy for Hurley I-II patients with both acute inflammatory lesions and fistulas, although more prospective studies, with higher sample sizes and standardized outcomes are needed to provide more scientific evidence.
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New trial: Dermaris-35: Clinical Evaluation of a Short Illumination Duration (35 Minutes) When Performing PDT of AK Using the Dermaris (clinicaltrials.gov) - Aug 30, 2022
P=N/A, N=25, Recruiting, Sponsor: Centre Dermatologique du Roy
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New trial: New Treatments for Actinic Keratoses of the Scalp (clinicaltrials.gov) - Jul 13, 2022
P=N/A, N=120, Active, not recruiting, Sponsor: Helsinki University Central Hospital
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment open: PhotodiVIN: Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia (clinicaltrials.gov) - Dec 17, 2021
P2, N=17, Recruiting, Sponsor: Institut de Canc
PDT seems to be cost-effective, safe, and well-tolerated local therapy for Hurley I-II patients with both acute inflammatory lesions and fistulas, although more prospective studies, with higher sample sizes and standardized outcomes are needed to provide more scientific evidence. Not yet recruiting --> Recruiting
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P2 trial: PhotodiVIN: Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia (clinicaltrials.gov) - Nov 2, 2021
P2, N=17, Not yet recruiting, Sponsor: Institut de Canc
- ||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Clinical, Journal, Adverse events: Optimizing treatment of acne with photodynamic therapy (PDT) to achieve long-term remission and reduce side effects. A prospective randomized controlled trial. (Pubmed Central) - Oct 8, 2021
A 1.5-h pre-treatment with the MAL cream was followed by illumination with red light (20 J/cm)...In comparison to baseline, the number of inflammatory lesions at 20 weeks on cheeks treated with MAL-PDT showed a relative decrease of 74% in the group with two treatments and 85% in the group with four treatments. This new treatment regimen for both MAL-PDT and red-light-only PDT, with shortened pre-treatment and reduced light dose, could be an effective modality.
- ||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov) - Oct 6, 2021
P3, N=130, Completed, Sponsor: Galderma R&D
This new treatment regimen for both MAL-PDT and red-light-only PDT, with shortened pre-treatment and reduced light dose, could be an effective modality. Active, not recruiting --> Completed
- |||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment closed: A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov) - Aug 23, 2021
P3, N=129, Active, not recruiting, Sponsor: Galderma R&D
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion date: A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov) - Aug 18, 2021
P3, N=129, Recruiting, Sponsor: Galderma R&D
Recruiting --> Active, not recruiting Trial completion date: Apr 2022 --> Aug 2021
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
[VIRTUAL] A randomized single-blinded prospective study to compare short incubation white light-emitting diode photodynamic therapy (PDT) with conventional PDT for the treatment of squamous cell carcinoma in situ () - Jul 5, 2021 - Abstract #BAD2021BAD_159;
To photosensitize the treatment area METVIX® (160 mg g–1 methyl aminolaevulinate) was applied 30 min before WL PDT and 3 h before cPDT...This is in contrast to the literature on actinic keratosis. Reporting well-designed negative studies is important to help plan future research and avoid exposing patient populations to treatments that have been previously proven to be ineffective.
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Clinical, Journal: Sensitization following occupational exposure to methyl aminolaevulinate - report of 2 cases. (Pubmed Central) - Jun 9, 2021
Reporting well-designed negative studies is important to help plan future research and avoid exposing patient populations to treatments that have been previously proven to be ineffective. No abstract available
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Journal: MAL-associated methyl nicotinate for topical PDT improvement. (Pubmed Central) - Jun 3, 2021
In vivo studies are showing that the incorporation of MN in the MAL cream increases the amount of PpIX produced in the tissue causing a higher effect on the epidermis after PDT. This improvement of the protocol may make the procedure more effective both in the destruction of tumor tissue and in the treatment of deeper cells decreasing possible recurrence, in addition to allowing improvements in the protocol, such as reducing the cream's incubation time.
- |||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: MAL DL-PDT and Calcitriol for AK treatment of the upper extremities MAL DL-PDT e Calcitriolo per le AK degli arti superiori (EUDRACT) - May 25, 2021
P3, N=36, Ongoing, Sponsor: ASL 1 AVEZZANO-SULMONA-L'AQUILA
- ||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion, Trial primary completion date: Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face (clinicaltrials.gov) - May 9, 2021
P3, N=465, Completed, Sponsor: Galderma R&D
This improvement of the protocol may make the procedure more effective both in the destruction of tumor tissue and in the treatment of deeper cells decreasing possible recurrence, in addition to allowing improvements in the protocol, such as reducing the cream's incubation time. Active, not recruiting --> Completed | Trial primary completion date: Nov 2020 --> Mar 2021
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Phase classification: COMET2: Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (clinicaltrials.gov) - Dec 10, 2020
P3b, N=131, Completed, Sponsor: Galderma
Active, not recruiting --> Completed | Trial primary completion date: Nov 2020 --> Mar 2021 Phase classification: P3 --> P3b
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment closed, Trial completion date: Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face (clinicaltrials.gov) - Dec 4, 2020
P3, N=465, Active, not recruiting, Sponsor: Galderma R&D
Phase classification: P3 --> P3b Recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Feb 2021
- | fluorouracil topical / Generic mfg.
Enrollment change: BOWTIE: Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease (clinicaltrials.gov) - Oct 26, 2020
P4, N=250, Recruiting, Sponsor: Maastricht University Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Feb 2021 N=168 --> 250
- ||||||| Ameluz (aminolevulinic acid) / Biofrontera
Trial completion: Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy (clinicaltrials.gov) - Oct 14, 2020
P3, N=281, Completed, Sponsor: Biofrontera Bioscience GmbH
N=168 --> 250 Active, not recruiting --> Completed
- [VIRTUAL] Real‐world efficacy of nanoemulsion aminolaevulinic acid daylight photodynamic therapy for the treatment of field cancerization () - Sep 9, 2020 - Abstract #BAD2020BAD_176;
Two prodrugs are currently used in the U.K.: an esterified formulation, methyl aminolaevulinate (Metvix; Galderma, Paris, France) and a nanoemulsion aminolaevulinic acid (Ameluz; Biofrontera AG, Leverkusen, Germany)...A total of 53 field cancerization patients underwent Ameluz daylight PDT, between May 2018 and August 2019, having failed to respond to either 5‐flurouracil, imiquimod and/or ingenol mebutate...In conclusion, daylight PDT was an effective treatment for field cancerization with nonhyperkeratotic AKs, irrespective of body site, and also hyperkeratotic AKs, notably on the dorsum of the hands. Although effective and convenient treatment for field cancerization, our findings suggest that after daylight PDT additional treatment may still be required for individual high‐risk hyperkeratotic AKs.
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion date, Trial primary completion date: A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov) - Jul 22, 2020
P3, N=129, Recruiting, Sponsor: Galderma R&D
Although effective and convenient treatment for field cancerization, our findings suggest that after daylight PDT additional treatment may still be required for individual high‐risk hyperkeratotic AKs. Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov) - Feb 13, 2020
P3, N=129, Recruiting, Sponsor: Galderma R&D
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment open: Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face (clinicaltrials.gov) - Dec 10, 2019
P3, N=465, Recruiting, Sponsor: Galderma R&D
Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Jun 2020 --> Dec 2021 Not yet recruiting --> Recruiting
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face (clinicaltrials.gov) - Sep 11, 2019
P3, N=465, Not yet recruiting, Sponsor: Galderma R&D
- | fluorouracil topical / Generic mfg.
Enrollment open: BOWTIE: Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease (clinicaltrials.gov) - Aug 14, 2019
P4, N=168, Recruiting, Sponsor: Maastricht University Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | fluorouracil topical / Generic mfg.
New P4 trial: Comparing surgical excision with photodynamic therapy and 5-Fluorouracil in treatment of Bowen'disease. Vergelijking van operatieve verwijdering met photodynamische therapie (PDT) en 5-Fluorouracil cr (EUDRACT) - May 14, 2019
P4, N=168, Ongoing, Sponsor: azM
- | fluorouracil topical / Generic mfg.
New P4 trial: BOWTIE: Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease (clinicaltrials.gov) - Apr 10, 2019
P4, N=168, Not yet recruiting, Sponsor: Maastricht University Medical Center
- | Cysview (hexaminolevulinate) / Photocure, Ameluz (aminolevulinic acid) / Biofrontera
Enrollment closed, Trial completion date, Trial primary completion date: Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL (clinicaltrials.gov) - Mar 28, 2019
P1/2, N=117, Active, not recruiting, Sponsor: Joint Authority for P
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2018 --> Sep 2018
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion, Enrollment change, Trial primary completion date: Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial (clinicaltrials.gov) - Jan 25, 2018
P=N/A, N=16, Completed, Sponsor: University Hospital, Ghent
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2018 --> Sep 2018 Recruiting --> Completed | N=20 --> 16 | Trial primary completion date: May 2018 --> May 2017
- | Ameluz (aminolevulinic acid) / Biofrontera
Trial completion: Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) (clinicaltrials.gov) - Nov 27, 2017
P4, N=72, Completed, Sponsor: Joint Authority for P
Recruiting --> Completed | N=20 --> 16 | Trial primary completion date: May 2018 --> May 2017 Active, not recruiting --> Completed
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change: AKtransplant: Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients (clinicaltrials.gov) - Sep 12, 2017
P4, N=10, Terminated, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed N=34 --> 10
- | Ameluz (aminolevulinic acid) / Biofrontera
Enrollment closed, Trial primary completion date: Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) (clinicaltrials.gov) - Apr 4, 2017
P4, N=72, Active, not recruiting, Sponsor: Joint Authority for P
N=34 --> 10 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Sep 2017
- ||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion, Enrollment change: SESAME: Metvix Daylight PDT in Actinic Keratosis (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=406, Completed, Sponsor: Galderma
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Completed | N=540 --> 406
- |||||||||| Ameluz (aminolevulinic acid) / Biofrontera
New P3 trial: Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy (clinicaltrials.gov) - Jun 15, 2016
P3, N=571, Completed, Sponsor: Biofrontera Bioscience GmbH
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: PDT-Bact (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=10, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Completed | N=540 --> 406 Active, not recruiting --> Completed
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment closed: PDT-Bact (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New trial: SESAME: Metvix Daylight PDT in Actinic Keratosis (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=540, Recruiting, Sponsor: Galderma